Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Ardizzoni

Showing results (31-40 of 369) with videos related to

Pageof 37
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 16, 2016
Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLCFrancesco Gelsomino, Valentina Ambrosini, Barbara Melotti, et al.
Tumori|August 19, 2008
Refractory pleural small cell carcinoma in never smoker. A case reportMarcello Tiseo, Elena Spiritelli, Marzia Capelletti, et al.
Anticancer Research|June 13, 2014
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysisMelissa Bersanelli, Marcello Tiseo, Fabrizio Artioli, et al.
Clinical Lung Cancer|November 13, 2021
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 MutationAlessandro Di Federico, Francesco Gelsomino, Dario De Biase, et al.
The Lancet. Oncology|July 4, 2014
BOLERO-3 results: pharmacological activity or pharmacokinetic effect?Sebastiano Buti, Melissa Bersanelli, Marcello Tiseo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2019
Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side EffectGiacomo Nuvola, Filippo Gustavo Dall'Olio, Barbara Melotti, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 9, 2020
A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease Receiving Steroid TherapyMaria Massucci, Francesca Di Fabio, Fabiola L Rojas Llimpe, et al.
Breast Cancer Research and Treatment|November 5, 2020
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessmentEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2020
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approachAndrea De Giglio, Marta Scorsetti, Davide Franceschini, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximabFrancesca Comito, Maria C Nigro, Francesca Sperandi, et al.
Pageof 37

Showing results (31-40 of 369) with videos related to

Sort By:
Pageof 37
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 16, 2016
Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLCFrancesco Gelsomino, Valentina Ambrosini, Barbara Melotti, et al.
Tumori|August 19, 2008
Refractory pleural small cell carcinoma in never smoker. A case reportMarcello Tiseo, Elena Spiritelli, Marzia Capelletti, et al.
Anticancer Research|June 13, 2014
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysisMelissa Bersanelli, Marcello Tiseo, Fabrizio Artioli, et al.
Clinical Lung Cancer|November 13, 2021
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 MutationAlessandro Di Federico, Francesco Gelsomino, Dario De Biase, et al.
The Lancet. Oncology|July 4, 2014
BOLERO-3 results: pharmacological activity or pharmacokinetic effect?Sebastiano Buti, Melissa Bersanelli, Marcello Tiseo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2019
Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side EffectGiacomo Nuvola, Filippo Gustavo Dall'Olio, Barbara Melotti, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 9, 2020
A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease Receiving Steroid TherapyMaria Massucci, Francesca Di Fabio, Fabiola L Rojas Llimpe, et al.
Breast Cancer Research and Treatment|November 5, 2020
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessmentEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2020
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approachAndrea De Giglio, Marta Scorsetti, Davide Franceschini, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximabFrancesca Comito, Maria C Nigro, Francesca Sperandi, et al.
Pageof 37